Shanghai Cingular Biotechnology Co's Zhongshan production base, backed by the Cuiheng Venture Capital Fund — a strategic partnership between Zhongshan Investment Holdings and Cuiheng Group — broke ground at the Zhongshan Life Science Park on August 21. 

With a 200 million yuan investment, the facility will occupy over 10,000 square meters in Building 14 of the park. Construction includes a 4,000-5,000 square meters state-of-the-art GMP production base, specializing in high-end medical devices such as cardiac valves and surgical patches for structural heart diseases.

Established in 2010, Cingular Biotech focuses on the R&D, manufacturing and commercialization of advanced biological medical products, with core expertise in structural cardiology.

Cuiheng Group has now launched 10 industrial investment funds totaling over 4.5 billion yuan, driving the relocation of over 30 tech enterprises to Cuiheng New District.